Hémopathies malignes
4 essais
MAIA
2019
Daratumumab + Lenalidomide/Dex in Transplant-Ineligible Myeloma
MURANO
2018
Venetoclax + Rituximab in Relapsed/Refractory CLL
ZUMA-1
2017
Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma
IRIS
2003
International Randomized Study of Interferon and STI571